Enpro (NPO) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 sales were $271.9M, down 1.8% year-over-year, with Sealing Technologies up 4.1% and Advanced Surface Technologies down 12.2% due to semiconductor market weakness.
Adjusted EBITDA rose 14.0% to $74.0M, with margin expanding 380 bps to 27.2% on gross margin gains and lower corporate expense.
Adjusted diluted EPS increased 13.7% to $2.08, reflecting EBITDA growth drivers.
Net income from continuing operations was $26.7M ($1.27/share) in Q2 2024, reversing a $18.6M loss last year.
Sealing Technologies segment delivered record profitability, while Advanced Surface Technologies showed sequential improvement.
Financial highlights
Q2 2024 net sales: $271.9M (down 1.8% year-over-year); organic sales declined 5.0%.
Adjusted EBITDA: $74.0M, up 14.0% year-over-year; margin 27.2%.
Adjusted diluted EPS: $2.08, up nearly 14% from the prior year.
Free cash flow for H1 2024 was $35.5M, down from $66.5M last year, mainly due to working capital timing and higher cash taxes.
Gross margin expanded by 230 bps to 43.8% due to pricing, mix, supply chain efficiencies, and AMI impact.
Outlook and guidance
2024 revenue expected to be approximately flat with 2023, revised from prior low- to mid-single-digit growth.
Adjusted EBITDA guidance narrowed to $260M–$270M; adjusted diluted EPS expected between $7.00–$7.60.
Recovery in semiconductor capital equipment spending expected to be gradual, with sequential improvement in AST for the remainder of 2024.
Sealing Technologies expected to follow normal seasonality, with a slightly stronger first half.
Capital expenditures projected at $33–35M for 2024; normalized tax rate at 25%.
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPO
Q3 202416 Jan 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPO
Q4 202423 Dec 2025 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPO
Proxy Filing1 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025 - Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPO
Proxy Filing1 Dec 2025